Madrigal Pharmaceuticals, Inc. (MDGL)
Nasdaq: MDGL · Pharmaceutical Preparations · West Conshohocken, PA · filing with the SEC since 2002
Who owns Madrigal Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
4
Janus Henderson Group PLC holds 8.8% of Common Stock, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
20
report now, of 36 people on the record since 2007. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Janus Henderson Group PLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 7% in Feb 17, 2026
Rebecca Taub, M.D.
SCHEDULE 13D/A · filed Dec 12, 2025 · Common Stock, Par Value $0.0001 Per Share
Paul A Friedman, M.D.
SCHEDULE 13D/A · filed Dec 12, 2025 · Common Stock, Par Value $0.0001 Per Share
Paulson & Co. Inc.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 7.5% in Feb 17, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What MDGL reports owning in othersstakes of 5% or more, and other ties
3 subsidiaries in 3 countries, from the list filed with the 10-K filed Feb 19, 2026.
Insider tradesForm 4
192sales
5purchases
171sales on a scheduled plan
8people selling
$73.9Msold, in dollars
$35.0Mbought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 36 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Friedman Paul A | Chief Executive Officer | 38 | $26.7M | 38 | 0 | $0 |
| Taub Rebecca | Pres., R&D, and CMO | 42 | $21.7M | 39 | 0 | $0 |
| Sibold William John | President and CEO | 37 | $10.5M | 24 | 0 | $0 |
| Levy Richard S | director | 26 | $7.4M | 26 | 0 | $0 |
| Dier Mardi | EVP and CFO | 28 | $3.8M | 27 | 0 | $0 |
| Huntsman Carole | Chief Commercial Officer | 14 | $1.7M | 13 | 0 | $0 |
| Kelley Shannon T | General Counsel | 5 | $1.3M | 3 | 0 | $0 |
| Soergel David | Chief Medical Officer | 2 | $1.0M | 1 | 0 | $0 |
| Baker Bros. Advisors LP | director | 0 | $0 | 0 | 5 | $35.0M |